Approach to Psychiatric Patient 2026 – Free Behavioral Medicine Practice Test and Study Guide

In treating an acute depressive episode, starting an SSRI such as sertraline or escitalopram is favored because they offer a good balance of effectiveness and tolerability, with a safer overdose profile than older drugs. The plan is to begin at a standard therapeutic dose and allow about 4–6 weeks to judge response, since this is roughly the time needed to see meaningful mood improvement for many patients.

Monitoring focuses on several key areas. First, assess efficacy—look for improvements in mood, energy, sleep, appetite, and functioning. If there is partial response after several weeks, consider increasing the dose or switching to another antidepressant; if there is no response, reassess diagnosis or explore augmentation strategies. Second, vigilantly monitor safety and tolerability: common adverse effects like nausea, sleep disturbance, or sexual dysfunction, and more serious concerns such as suicidality, which requires careful attention especially early in treatment and in younger patients. Third, track weight and blood pressure, recognizing that different agents and related medications can affect these parameters. Fourth, be mindful of drug interactions, given the patient’s other medications, because SSRIs can interact via liver enzymes. Finally, plan a gradual taper when stopping to minimize discontinuation syndromes.

Other options don’t fit as first-line choices for a typical acute depressive episode. MAO inhibitors carry strict dietary and drug interaction restrictions and pose risks that make them a less desirable first option. Tricyclic antidepressants have higher risk in overdose and more troubling anticholinergic and cardiovascular side effects, necessitating closer monitoring. Atypical antipsychotics may be used as augmentation or for depressive episodes with psychotic features or treatment resistance, but they’re not considered first-line monotherapy for a straightforward acute depression.